hotspot -WSS

hotspot

author：leisure time 2025-09-27 23:00:48 - browse：48983

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： With trial win, GSK could get blood cancer drug back on market

knowledge

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

GOP presidential candidates start declaring their loyalty

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

ASCO: Palliative care found as helpful given virtually as in person

With trial win, GSK could get blood cancer drug back on market

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

Let's speed up science by embracing open access publishing

Trump demands the U.S. pay no more for drugs than other countries … again

Cord blood banking comes at a high cost to babies

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The history of OxyContin, told through Purdue Pharma documents

How to save PrEP access — and even expand it

Maui funeral service workers on devastation of fires: 'I'm in shock'

Heart attack and stroke risk calculators need revising

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

entertainment

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Target recalls 2.2 million additional candles due to laceration, burn hazards

Ultragenyx gene therapy for rare liver ailment succeeds in late

Kim Kardashian sparks debate on benefits of full

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

ASCO: AstraZeneca says CAR

Wikipedia

knowledge

knowledge

entertainment